NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹190.05
- Market cap
- ₹211.3 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.9×Sector 45.9×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Other results update announcements
All →Atul Auto Results Update
Atul Auto reported H1 FY27 consolidated revenue of ₹486.74 crore, up 38%, and PAT of ₹14.88 crore, up 44%. Q2 PAT fell 17% year-on-year to ₹6.84 crore.
Gem Aromatics Results Update
Gem Aromatics' Q2FY27 press release shows consolidated revenue of Rs 104 Crore but a Rs 7 Crore consolidated loss. Standalone PAT rose to Rs 8.9 Crore.
OBSC Perfection Results Update
OBSC Perfection released a press release on unaudited September 2026 half-year results. The release reports record total income, EBITDA and profit.
Mangal Electrical Industries Results Update
Mangal Electrical released a press release on unaudited September 2026 quarter results. CRGO volumes rose about 63% year on year.
Sarda Energy & Minerals Results Update
Sarda Energy & Minerals reported Q2 and H1 FY27 results via press release, with H1 EBITDA at Rs 1,326 Cr (up 3.9%) and PAT at Rs 799 Cr. It also announced a manganese ore block win in Andhra Pradesh through a subsidiary.
Sugs Lloyd Results Update
Sugs Lloyd reported H1 FY27 revenue of Rs.213.31 Crore and PAT of Rs.20.01 Crore, up 73% and 69% YoY. The release also cites Rs.1,068 Crore order book and Rs.395 Crore Q2 order inflow.